Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Schiller Website

John T. Schiller, Ph.D.

Selected Publications

1)  Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR.
Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica.
PLoS ONE. 8: e68329, 2013.
2)  Schiller JT, Lowy DR.
Virus Infection and Cancer: an Overview.
Recent Results in Cancer Research. 193: 1-10, 2013.
3)  Safaeian M, Kemp TJ, Pan DY, Porras C, Cecilia Rodriguez A, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial.
Hum Vaccin Immunother. 9, 2013.
4)  Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT.
Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.
J. Virol. 87: 3862-70, 2013.
5)  Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D.
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.
Mucosal Immunol. 6: 393-404, 2013.
6)  Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang H, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
J. Virol. [Epub ahead of print], 2013.
7)  Schiller JT, Castellsagué X, Garland SM.
A review of clinical trials of human papillomavirus prophylactic vaccines.
Vaccine. 30 Suppl 5: F123-38, 2012.
8)  Day PM, Pang YS, Kines RC, Thompson CD, Lowy DR, Schiller JT.
An HPV in vitro neutralization assay that recapitulates the in vivo process of infection provides a sensitive measure of L2 infection-inhibiting antibodies.
Clin Vaccine Immunol. 19: 1075-82, 2012.
9)  Schelhaas M, Shah B, Holzer M, Blattmann P, Kühling L, Day PM, Schiller JT, Helenius A.
Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis.
PLoS Pathog. 8: e1002657, 2012.
10)  Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT.
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
J. Clin. Invest. 122: 4606-20, 2012.
11)  Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).
Vaccine. 31: 165-70, 2012.
12)  Handisurya A, Day PM, Thompson CD, Buck CB, Kwak K, Roden RB, Lowy DR, Schiller JT.
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.
Virology. 433: 385-94, 2012.
13)  Lowy DR, Schiller JT.
Reducing HPV-associated cancer globally.
Cancer Prev Res (Phila). 5: 18-23, 2012.
14)  Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G.
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.
J. Immunol. 188: 714-23, 2012.
15)  Schiller JT, Lowy DR.
Understanding and learning from the success of prophylactic human papillomavirus vaccines.
Nat. Rev. Microbiol. 10: 681-92, 2012.
16)  Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D.
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.
J. Virol. 85: 13253-9, 2011.
17)  Schiller JT, Buck CB.
Cutaneous squamous cell carcinoma: a smoking gun but still no suspects.
J. Invest. Dermatol. 131: 1595-6, 2011.
18)  Roberts JN, Kines RC, Katki HA, Lowy DR, Schiller JT.
Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.
J. Natl. Cancer Inst. 103: 737-43, 2011.
19)  Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R.
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
Lancet Oncol. 12: 862-70, 2011.
20)  Hanumantha Rao N, Baji Babu P, Rajendra L, Sriraman R, Pang YS, Schiller JT, Srinivasan VA.
Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
Vaccine. 29: 7326-34, 2011.
21)  Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
Vaccine. 29: 2011-4, 2011.
22)  Mitsunaga M, Kosaka N, Kines RC, Roberts JN, Lowy DR, Schiller JT, Ishihara Y, Hasegawa A, Choyke PL, Kobayashi H.
In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system.
Cancer Prev Res (Phila). 4: 767-73, 2011.
23)  Decrausaz L, Domingos-Pereira S, Duc M, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D.
Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
Int. J. Cancer. 129: 762-72, 2011.
24)  Herrero R, Wacholder S, Rodríguez AC, Solomon D, González P, Kreimer AR, Porras C, Schussler J, Jiménez S, Sherman ME, Quint W, Schiller JT, Lowy DR, Schiffman M, Hildesheim A.
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica.
Cancer Discov. 1: 408-419, 2011.
25)  Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S.
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
J. Natl. Cancer Inst. 103: 1444-51, 2011.
26)  Schiller JT, Day PM, Kines RC.
Current understanding of the mechanism of HPV infection.
Gynecol. Oncol. 118: S12-7, 2010.
27)  Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, Chackerian B, Peabody DS.
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.
Vaccine. 28: 4384-93, 2010.
28)  Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT.
In vivo mechanisms of vaccine-induced protection against HPV infection.
Cell Host Microbe. 8: 260-70, 2010.
29)  Graham BS, Kines RC, Corbett KS, Nicewonger J, Johnson TR, Chen M, Lavigne D, Roberts JN, Cuburu N, Schiller JT, Buck CB.
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.
Mucosal Immunol. 3: 475-86, 2010.
30)  Schiller JT, Lowy DR.
Vaccines To Prevent Infections by Oncoviruses.
Annu Rev Microbiol. 64: 23-41, 2010.
31)  Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D.
Clinician's guide to human papillomavirus immunology: knowns and unknowns.
Lancet Infect Dis. 9: 347-56, 2009.
32)  Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
J. Natl. Cancer Inst. 101: 782-92, 2009.
33)  Schiller JT, Lowy DR.
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.
J. Infect. Dis. 200: 166-71, 2009.
34)  Lee T, Kim Y, Yoon S, Choi J, Yang J, Kim C, Schiller JT, Sung M, Poo H.
Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect.
Cancer Immunol. Immunother. 58: 1781-94, 2009.
35)  Cantarella G, Liniger M, Zuniga A, Schiller JT, Billeter M, Naim HY, Glueck R.
Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma.
Vaccine. 27: 3385-90, 2009.
36)  Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM.
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.
J. Virol. 83: 2067-74, 2009.
37)  Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YY, Holmgren J, Stadler K, Schiller JT, Anjuère F, Czerkinsky C.
Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.
J. Immunol. 183: 7851-9, 2009.
38)  Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM.
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.
Proc. Natl. Acad. Sci. U.S.A. 106: 20458-63, 2009.
39)  Day PM, Schiller JT.
The role of furin in papillomavirus infection.
Future Microbiol. 4: 1255-62, 2009.
40)  Talwar GP, Dar SA, Rai MK, Reddy KV, Mitra D, Kulkarni SV, Doncel GF, Buck CB, Schiller JT, Muralidhar S, Bala M, Agrawal SS, Bansal K, Verma JK.
A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens.
Int. J. Antimicrob. Agents. 32: 180-5, 2008.
41)  Schiller JT, Castellsagué X, Villa LL, Hildesheim A.
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Vaccine. 26 Suppl 10: K53-61, 2008.
42)  Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL.
Arrangement of L2 within the papillomavirus capsid.
J. Virol. 82: 5190-7, 2008.
43)  Kemp TJ, Hildesheim A, Falk RT, Schiller JT, Lowy DR, Rodriguez AC, Pinto LA.
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.
Clin. Vaccine Immunol. 15: 60-4, 2008.
44)  Day PM, Lowy DR, Schiller JT.
Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.
J. Virol. 82: 12565-8, 2008.
45)  Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M.
Human papillomavirus infection and the primary and secondary prevention of cervical cancer.
Cancer. 113: 1980-93, 2008.
46)  Schelhaas M, Ewers H, Rajamäki ML, Day PM, Schiller JT, Helenius A.
Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions.
PLoS Pathog. 4: e1000148, 2008.
47)  Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT.
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
J. Virol. 82: 4638-46, 2008.
48)  Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlstrom KR, Schiller JT, Wei Q, Li G.
p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers.
Carcinogenesis. 29: 875-9, 2008.
49)  Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RB.
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
Proc. Natl. Acad. Sci. U.S.A. 105: 5850-5, 2008.
50)  Chackerian B, Durfee MR, Schiller JT.
Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model.
J. Immunol. 180: 5816-25, 2008.
51)  García-Piñeres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, Lowy DR, Schiller JT, Pinto LA.
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
Clin. Vaccine Immunol. 14: 984-9, 2007.
52)  Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR.
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
JAMA. 298: 743-53, 2007.
53)  Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT.
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
Nat. Med. 13: 857-61, 2007.
54)  Revaz V, Zurbriggen R, Moser C, Schiller JT, Ponci F, Bobst M, Nardelli-Haefliger D.
Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Antiviral Res. 76: 75-85, 2007.
55)  Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
J. Virol. 81: 8784-92, 2007.
56)  Frazer IH, Lowy DR, Schiller JT.
Prevention of cancer through immunization: Prospects and challenges for the 21st century.
Eur. J. Immunol. 37 Suppl 1: S148-55, 2007.
57)  Kämper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M.
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.
J. Virol. 80: 759-68, 2006.
58)  Buck CB, Thompson CD, Roberts JN, Müller M, Lowy DR, Schiller JT.
Carrageenan is a potent inhibitor of papillomavirus infection.
PLoS Pathog. 2: e69, 2006.
59)  Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A.
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Virology. 353: 451-62, 2006.
60)  Schiller JT, Nardelli-Haefliger D.
Chapter 17: Second generation HPV vaccines to prevent cervical cancer.
Vaccine. 24 Suppl 3: S147-53, 2006.
61)  Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC.
Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer.
Vaccine. 24 Suppl 3: S242-9, 2006.
62)  Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, Meheus A.
Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.
Vaccine. 24 Suppl 3: S251-61, 2006.
63)  Richards RM, Lowy DR, Schiller JT, Day PM.
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.
Proc. Natl. Acad. Sci. U.S.A. 103: 1522-7, 2006.
64)  Qian J, Dong Y, Pang YY, Ibrahim R, Berzofsky JA, Schiller JT, Khleif SN.
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Int. J. Cancer. 118: 3022-9, 2006.
65)  Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT.
Human alpha-defensins block papillomavirus infection.
Proc. Natl. Acad. Sci. U.S.A. 103: 1516-21, 2006.
66)  Kamangar F, Qiao YL, Schiller JT, Dawsey SM, Fears T, Sun XD, Abnet CC, Zhao P, Taylor PR, Mark SD.
Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China.
Int. J. Cancer. 119: 579-84, 2006.
67)  Lowy DR, Schiller JT.
Prophylactic human papillomavirus vaccines.
J. Clin. Invest. 116: 1167-73, 2006.
68)  Schiller JT, Lowy DR.
Prospects for cervical cancer prevention by human papillomavirus vaccination.
Cancer Res. 66: 10229-32, 2006.
69)  Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB.
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology. 337: 365-72, 2005.
70)  Buck CB, Pastrana DV, Lowy DR, Schiller JT.
Generation of HPV pseudovirions using transfection and their use in neutralization assays.
Methods Mol. Med. 119: 445-62, 2005.
71)  Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, Berzofsky JA, Hildesheim A.
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
Vaccine. 23: 3555-64, 2005.
72)  Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, Ponci F, De Grandi P.
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
Vaccine. 23: 3634-41, 2005.
73)  Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT.
Maturation of papillomavirus capsids.
J Virol. 79: 2839-46, 2005.
74)  Lenz P, Lowy DR, Schiller JT.
Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
Eur J Immunol. 35: 1548-56, 2005.
75)  Schiller J, Lowy D.
Rohan T, Shah K, eds.
Preventive human papillomavirus vaccines. In: Cervical Cancer: From Etiology to Prevention.
Norwell: Kluwer Academic Publishers; 2004. p. 325-43 [Book Chapter]
76)  Schiller J, Lowy D.
Plotkin S, Orenstein W, eds.
HPV vaccines for cervical cancer prevention. In: Vaccines. Volume 4th edition.
Philadelphia: Elsevier Inc.; 2004. p. 1259-65 [Book Chapter]
77)  Silins I, Wang X, Tadesse A, Jansen KU, Schiller JT, Avall-Lundqvist E, Frankendal B, Dillner J.
A population-based study of cervical carcinoma and HPV infection in Latvia.
Gynecol Oncol. 93: 484-92, 2004.
78)  Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, Sankaranarayanan R, Schiller J, Singer A, Wright TC, Kinney W, Meijer CJ, Linder J, McGoogan E, Meijer C, Wright T.
Cervical cancer control, priorities and new directions.
Int. J. Cancer. 108: 329-33, 2004.
79)  Buck CB, Pastrana DV, Lowy DR, Schiller JT.
Efficient intracellular assembly of papillomaviral vectors.
J Virol. 78: 751-7, 2004.
80)  Day PM, Baker CC, Lowy DR, Schiller JT.
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.
Proc Natl Acad Sci USA. 101: 14252-14257, 2004.
81)  Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT.
Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus.
J Virol. 78: 4037-47, 2004.
82)  Li Q, Cao C, Chackerian B, Schiller J, Gordon M, Ugen KE, Morgan D.
Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice.
BMC Neurosci. 5:21, 2004.
83)  Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT.
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Virology. 321: 205-16, 2004.
84)  Schiller JT, Davies P.
Science and society: Delivering on the promise: HPV vaccines and cervical cancer.
Nat Rev Microbiol. 2: 343-7, 2004.
85)  Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
J Infect Dis. 188: 327-38, 2003.
86)  Nonnenmacher B, Pintos J, Bozzetti MC, Mielzinska-Lohnas I, Lorincz AT, Ikuta N, Schwartsmann G, Villa LL, Schiller JT, Franco E.
Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer.
Int J STD AIDS. 14: 258-65, 2003.
87)  Da Silva DM, Schiller JT, Kast WM.
Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.
Vaccine. 21: 3219-27, 2003.
88)  Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El-Naggar AK, Spitz MR, Schiller JT, Wei Q, Sturgis EM.
Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis.
Clin Cancer Res. 9: 2620-6, 2003.
89)  Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT.
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.
Clin Immunol. 106: 231-7, 2003.
90)  Day PM, Lowy DR, Schiller JT.
Papillomaviruses infect cells via a clathrin-dependent pathway.
Virology. 307: 1-11, 2003.
91)  Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P.
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.
J Natl Cancer Inst. 95: 1128-37, 2003.
92)  Chackerian B, Lenz P, Lowy DR, Schiller JT.
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles.
J Immunol. 169: 6120-6, 2002.
93)  Wong M, Pagano JS, Schiller JT, Tevethia SS, Raab-Traub N, Gruber J.
New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer.
J Natl Cancer Inst. 94: 1832-6, 2002.
94)  Pastrana DV, Vass WC, Lowy DR, Schiller JT.
An HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
Virology. 279: 361-369, 2001.
95)  Chackerian B, Lowy DR, Schiller JT.
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.
J Clin Invest. 108: 415-423, 2001.
96)  Da Silva DM, Pastrana DV, Schiller JT, Kast WM.
Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Virology. 290: 350-60, 2001.
97)  Carr EA, Théon AP, Madewell BR, Hitchcock ME, Schlegel R, Schiller JT.
Expression of a transforming gene (E5) of bovine papillomavirus in sarcoids obtained from horses.
Am. J. Vet. Res. 62: 1212-7, 2001.
98)  Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL.
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse).
Cancer Epidemiol. Biomarkers Prev. 10: 101-6, 2001.
99)  Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Møller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J.
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.
N. Engl. J. Med. 344: 1125-31, 2001.
100)  Okun MM, Day PM, Greenstone HL, Booy FP, Lowy DR, Schiller JT, Roden RB.
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.
J Virol. 75: 4332-42, 2001.
101)  Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D.
Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Virology. 279: 354-60, 2001.
102)  Schiller JT, Lowy DR.
Papillomavirus-like particle based vaccines: cervical cancer and beyond.
Expert Opin Biol Ther. 1: 571-581, 2001.
103)  Schiller JT, Lowy DR.
Papillomavirus-like particle vaccines.
J. Natl. Cancer Inst. Monographs. 50-4, 2001.
104)  Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT.
Papillomavirus-like particles induce acute activation of dendritic cells.
J Immunol. 166: 5346-5355, 2001.
105)  Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM.
Physical interaction of human papillomavirus virus-like particles with immune cells.
Int. Immunol. 13: 633-41, 2001.
106)  Roden RB, Day PM, Bronzo BK, Yutzy WH, Yang Y, Lowy DR, Schiller JT.
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.
J Virol. 75: 10493-7, 2001.
107)  Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR.
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
J Natl Cancer Inst. 93: 284-292, 2001.
108)  Schiller JT, Hidesheim A.
Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report.
J. Clin. Virol. 19: 67-74, 2000.
109)  Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT.
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Virology. 270: 254-257, 2000.
110)  Chackerian B, Lowy DR, Schiller JT.
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.
Proc Natl Acad Sci U S A. 96: 2373-2378, 1999.
111)  Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT.
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Proc Natl Acad Sci U S A. 95: 1800-1805, 1998.
112)  Day PM, Roden RB, Lowy DR, Schiller JT.
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains.
J Virol. 72: 142-150, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 9/9/2013.